TransMedics Group (NASDAQ:TMDX) Reaches New 12-Month Low – Time to Sell?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) reached a new 52-week low on Monday . The company traded as low as $58.27 and last traded at $58.71, with a volume of 304971 shares traded. The stock had previously closed at $61.02.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMDX. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Piper Sandler decreased their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

The firm has a market capitalization of $2.09 billion, a PE ratio of 66.33 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a fifty day moving average price of $79.19 and a 200-day moving average price of $124.90.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.12) EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,459 shares of company stock worth $1,802,244 over the last three months. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently modified their holdings of the stock. Driehaus Capital Management LLC grew its position in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. Hood River Capital Management LLC purchased a new stake in TransMedics Group during the 2nd quarter valued at about $18,854,000. Canada Pension Plan Investment Board purchased a new stake in TransMedics Group in the second quarter valued at approximately $16,086,000. Finally, Public Sector Pension Investment Board purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at $11,079,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.